Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 159

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 159
---
 operations.

Foreign currency exchange rate fluctuations

Our operations are currently conducted almost entirely in the United States as international markets contribute less
than 1% of our revenue. If we choose to expand internationally, our results of operations and cash flows may become subject to fluctuations due to changes in foreign currency exchange rates. In periods when the U.S. dollar declines in value as
compared to the foreign currencies in which we incur expenses, our foreign currency-based expenses will increase when translated into U.S. dollars. In addition, future fluctuations in the value of U.S. dollar may affect the price at which we sell
our tests outside the United States. To date, our foreign currency risk has been minimal.

Critical accounting estimates

We prepare our financial statements in conformity with GAAP. The preparation of financial statements in conformity with GAAP required certain estimates and assumptions
to be made that may affect our financial statements. Accounting policies that have a significant impact on our results are described in Note 2 to our financial statements included elsewhere in this prospectus. The accounting policies discussed in
this section are

112

those that we consider to be the most critical. We consider an accounting policy to be critical if the policy is subject to a material level of judgment and if changes in those judgments are
reasonably likely to materially impact our results.

We base our estimates and judgments on reasonably available information. Our estimates and assumptions may
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ
from those estimates and such differences may be material to the financial statements.

We continue to monitor and assess our critical estimates in light of
developments, and as new events occur and additional information is obtained, our estimates may change materially in future periods.

Revenue

We generate revenue primarily from our prenatal and oncology testing services, which are referred to as testing services or test results. We consider the patient as our
customer, that requests our test service through their physician. Test results are the single performance obligation being provided to customers. Testing service revenue is recognized at a point in time when test results are delivered to the
ordering physician. We generally bill an insurance carrier, Medicaid or a patient or a combination of both upon delivery of test results. test results. The amount of revenue recognized reflects the consideration we expect to be entitled to receive
in exchange for the test results.

We recognize revenue upon transfer of control of promised goods and services